Search AMRN
AMARIN CORP PLC\UK
Nasdaq · CIK 897448
Last close12.35
Daily change-0.37 (-2.91%)
10 Years gain-80.70%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AMRN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
30.1Momentum
64.3Acceleration
54.9Confidence
90.0Annual Revenue13
Quarterly Revenue55
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.3 / 25
Quality5.2 / 25
Capital Efficiency2.2 / 20
Balance Sheet15.0 / 15
Shareholder Economics5.9 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 2.8521 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 5.5051 percentage points.
Key Metrics
Revenue Growth TTM0.69%OK
Revenue CAGR 3Y-16.67%OK
Gross Margin50.22%OK
Operating Margin-24.04%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-18.09%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.73%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $213.65M | $120.87M | -$50.17M | $6.73M | n/a | 56.57% | -23.48% | n/a | -22.74% | 414.98M |
| 2025 FY Dec 31, 2024 | $228.61M | $81.38M | -$91.80M | -$31.02M | n/a | 35.6% | -40.15% | n/a | -34.26% | 410.94M |
| 2025 FY Dec 31, 2023 | $306.91M | $165.54M | -$67.59M | $6.88M | n/a | 53.94% | -22.02% | n/a | -20.64% | 407.66M |
| 2024 FY Dec 31, 2022 | $369.19M | $242.48M | -$105.87M | -$180.09M | n/a | 65.68% | -28.68% | n/a | -33.53% | 401.16M |
| 2023 FY Dec 31, 2021 | $583.19M | $461.86M | $10.50M | -$66.54M | n/a | 79.2% | 1.8% | n/a | n/a | 402.48M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $209.75M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-323845, 0001193125-25-254621 |
| Revenue Growth TTM | 0.69% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-323845, 0001193125-25-254621 |
| Revenue CAGR 3Y | -16.67% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-085818 |
| Revenue CAGR 5Y | -19.04% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-085818 |
| Gross Profit CAGR 3Y | -20.71% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-085818 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-323845, 0001193125-25-254621 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 50.22% | Gross Profit / Revenue | OK | 0001193125-26-323845, 0001193125-25-254621 |
| Operating Margin | -24.04% | Operating Income / Revenue | OK | 0001193125-26-323845, 0001193125-25-254621 |
| ROIC | -18.09% | NOPAT / Average Invested Capital | OK | 0001193125-26-323845, 0001193125-25-254621 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-323845 |
| Current Ratio | 3.67x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.50 | Revenue / Diluted Shares | OK | 0001193125-26-323845, 0001193125-25-254621 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |